Guided Therapeutics Inc. (OTCMKTS:GTHP) Short Interest Down 38.5% in January

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the target of a significant decline in short interest during the month of January. As of January 30th, there was short interest totaling 17,754 shares, a decline of 38.5% from the January 15th total of 28,887 shares. Based on an average trading volume of 9,930 shares, the short-interest ratio is presently 1.8 days. Currently, 0.1% of the company’s shares are short sold. Currently, 0.1% of the company’s shares are short sold. Based on an average trading volume of 9,930 shares, the short-interest ratio is presently 1.8 days.

Guided Therapeutics Price Performance

Shares of Guided Therapeutics stock traded down $0.09 during trading on Friday, hitting $0.30. The stock had a trading volume of 30,212 shares, compared to its average volume of 6,036. Guided Therapeutics has a 12 month low of $0.06 and a 12 month high of $0.54. The firm’s fifty day simple moving average is $0.38 and its 200-day simple moving average is $0.29. The stock has a market cap of $26.00 million, a PE ratio of -6.02 and a beta of 0.61.

Guided Therapeutics (OTCMKTS:GTHP) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.01) EPS for the quarter. The company had revenue of $0.06 million for the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.